Recent Finacing
Recent Raise
Soricimed develops targeted solid-tumor therapies derived from Northern Short-tailed Shrew venom peptides, advancing TRPV6-targeting candidate SOR-C13 in clinical trials and preclinical PDC and PRRT programs.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at Soricimed.
